NCT00017043已完成2 期
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Metastatic Gastric Adenocarcinoma Previously Treated With a Taxane
Bristol-Myers Squibb1 个研究点 分布在 1 个国家开始时间: 2001年2月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic stomach cancer previously treated with chemotherapy.
详细描述
OBJECTIVES:
- Determine the clinical activity of BMS-247550, in terms of response rate, in patients with previously treated metastatic gastric adenocarcinoma.
- Determine the safety of this drug in these patients.
- Assess the response duration, time to progression, and survival of patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days for 2-18 courses in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses after confirmation of CR.
Patients are followed every 3 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
BMS-247550 in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00033306University of Alabama at Birmingham2
已完成
2 期
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With ChemotherapyGastric CancerEsophageal CancerNCT00017056Memorial Sloan Kettering Cancer Center
已完成
2 期
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal CancerColorectal CancerNCT00022477University of Chicago24
已完成
2 期
BMS-247550 in Treating Women With Metastatic Breast CancerBreast CancerNCT00020904Memorial Sloan Kettering Cancer Center
已完成
2 期
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00016393SWOG Cancer Research Network